Dr Westervelt speaks with ecancer at EHA 23 about pre-clinical and early clinical results of a CD3/33 bi-specific T cell engager (BiTE) to treat AML.

He outlines the data from early mouse models and human cell cultures which showed activity of the molecule, and the pharmacodynamics seen in this phase I trial.

Dr Westervelt describes the escalating doses of the trial, noting a single incidence of grade 2 cytokine release syndrome, and sets out near-term goals for further trial expansion and validation.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.